Applicare extends contract with Picker
Applicare extends contract with PickerContrary to speculation that GE Medical Systems’ acquisition of Applicare Medical Imaging would impact the Dutch PACS firm’s OEM distribution relationships (PNN 6/99), Applicare has extended
Applicare extends contract with Picker
Contrary to speculation that GE Medical Systems acquisition of Applicare Medical Imaging would impact the Dutch PACS firms OEM distribution relationships (
PNN
6/99), Applicare has extended its PACS software supply contract with key partner Picker International through 2004. Cleveland-based Picker has been integrating Applicares RadWorks software into its PACS since 1997 and plans to continue beta testing RadWorks 5.0 with such institutions as the University of Utah and the University of Wisconsin. Picker claims an installed base of nearly 500 Radworks licenses in the U.S. and other countries.
The contract extension is further proof that we take our multichannel strategy seriously and that well support Picker with product development for years to come, said Ruud Kroon, Applicare CEO.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
